Modified FOLFOX-6 Protocol
Modified FOLFOX-6 (mFOLFOX6) is a chemotherapy regimen consisting of oxaliplatin 85 mg/m² IV over 2 hours, leucovorin 400 mg/m² IV over 2 hours (given concurrently with oxaliplatin in separate bags), followed by fluorouracil 400 mg/m² IV bolus, then fluorouracil 2,400 mg/m² as a continuous infusion over 46 hours, repeated every 14 days. 1
Regimen Components and Administration
The protocol is administered on a 2-week cycle:
Day 1:
- Oxaliplatin 85 mg/m² IV infusion over 2 hours
- Leucovorin 400 mg/m² IV infusion over 2 hours (simultaneously with oxaliplatin via Y-connector)
- Fluorouracil 400 mg/m² IV bolus immediately after
- Fluorouracil 2,400 mg/m² continuous IV infusion over 46 hours (using pump device)
Day 2:
Clinical Indications
mFOLFOX6 is FDA-approved for:
- Adjuvant treatment of stage III colon cancer after complete resection (continue for up to 12 cycles or until unacceptable toxicity)
- Advanced/metastatic colorectal cancer (continue until disease progression or unacceptable toxicity) 1
For adjuvant stage III colon cancer, discontinue oxaliplatin after 3 months (6 cycles) while continuing fluorouracil/leucovorin to complete 6 months total treatment in low-risk patients (T1-3, N1). For high-risk patients (T4 and/or N2), complete the full 6 months of oxaliplatin-containing therapy. 3, 2
Key Management Considerations
Oxaliplatin-Related Neuropathy
Discontinue oxaliplatin from mFOLFOX6 after 3 months of therapy, or sooner for unacceptable neurotoxicity, while maintaining fluorouracil/leucovorin for the entire 6 months or until progression. 3
Critical patient instructions:
- Avoid all cold exposure (cold drinks, ice cubes, cold objects, cold outdoor temperatures)
- Cover skin when going outdoors in cold weather
- Never apply ice or ice packs to the body
- Cold exposure can trigger or worsen acute neuropathy symptoms 1
Hematologic Monitoring
Delay treatment until neutrophils ≥1.5 × 10⁹/L and platelets ≥75 × 10⁹/L. Withhold for sepsis or septic shock. Dose reduce after recovery from grade 4 neutropenia, febrile neutropenia, or grade 3-4 thrombocytopenia. 1
Hypersensitivity Risk
Permanently discontinue oxaliplatin immediately for any hypersensitivity reaction, including anaphylaxis, which can occur within minutes of administration and during any cycle. This is a black box warning. 1
Important Contraindications and Precautions
- Contraindicated in patients with prior hypersensitivity to oxaliplatin or platinum-based drugs
- Monitor liver function tests at baseline, before each cycle, and as clinically indicated
- Avoid in patients with congenital long QT syndrome; monitor ECGs in patients with heart failure or arrhythmias
- Can cause Posterior Reversible Encephalopathy Syndrome (PRES) - permanently discontinue if this occurs 1
Efficacy Data
In the NCCN guidelines, FOLFOX and CAPEOX are considered interchangeable for metastatic colorectal cancer, with panel consensus supporting their equivalent efficacy. 3 The regimen demonstrates objective response rates of 53-81% in various gastrointestinal malignancies depending on disease setting and prior treatment exposure. 4, 5